ACE and atrial fibrillation: A meta-analysis conducted by Healey, J.S. et al. in 2005 included 11 randomized controlled human trials and demonstrated a 28% reduction in the risk of AF in angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB) users compared to non-users (43).